SCHEMBL6879575

SCHEMBL6879575

COC(=O)c1ccc(-c2ccc(OC)c(C(C)(C)C)c2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.50
RARB P10826 1/20 0.50
RARG P13631 1/20 0.50
HPGD P15428 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 4/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HSD17B2 P37059 4/20 0.44
HSD17B1 P14061 3/20 0.44
ERN1 O75460 3/20 0.44
OPRD1 P41143 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7024481 0.90 RARA (0.58) RARARARBRARGHPGDALDH1A1
SCHEMBL6876549 0.83 RARA (0.50) RARARARBRARGHPGDALDH1A1
SCHEMBL6477476 0.80 KDM4E (0.58) HPGDALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL27141132 0.77 RAB9A (0.54) HPGDALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL6870481 0.77 RARA (0.46) RARARARBRARGHPGDALDH1A1
SCHEMBL2550687 0.76 KDM4E (0.72) HPGDALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL6874825 0.76 RARA (0.45) RARARARBRARGALDH1A1MAPT
SCHEMBL6877068 0.76 RARA (0.48) RARARARBRARGHPGDALDH1A1
SCHEMBL6876542 0.76 MAPK1 (0.50) RARARARBRARGHPGDALDH1A1
SCHEMBL6876543 0.76 MAPK1 (0.50) RARARARBRARGHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825360-B1 Bicyclic aromatic compounds GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-11-30 US disclosed
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics BERNARDON JEAN-MICHEL 2003-07-17 US disclosed
US-20030060491-A1 Bicyclic aromatic compounds BERNARDON JEAN-MICHEL (FR) 2003-03-27 US disclosed
US-6515021-B1 Bicyclic aromatic compounds CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2003-02-04 US disclosed
US-6147255-A TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060491-A1 Bicyclic aromatic compounds MITF, TYR, PAH RARA 451/4885RARB 529/4885RARG 474/4885
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics MITF, TYR, PAH RARA 52/4885RARB 93/4885RARG 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.